Literature DB >> 11592083

Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice.

H Firat1, S Tourdot, A Ureta-Vidal, A Scardino, A Suhrbier, F Buseyne, Y Rivìere, O Danos, M L Michel, K Kosmatopoulos, F A Lemonnier.   

Abstract

HLA-A*0201 transgenic, H-2D(b)/mouse beta2-microglobulin double-knockout mice were used to compare and optimize the immunogenic potential of 17HIV 1-derived,HLA-A0201-restricted epitopic peptides. A tyrosine substitution in position 1 of the epitopic peptides, which increases both their affinity for and their HLA-A0201 molecule stabilizing capacity, was introduced in a significant proportion, having verified that such modifications enhance their immunogenicity in respect of their natural antigenicity. Based on these results, a 13-polyepitope construct was inserted in the pre-S2 segment of the hepatitis B middle glycoprotein and used for DNA immunization. Long-lasting CTL responses against most of the inserted epitopes could be elicited simultaneously in a single animal with cross-recognition in several cases of their most common natural variants.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592083     DOI: 10.1002/1521-4141(2001010)31:10<3064::aid-immu3064>3.0.co;2-l

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  CombiHIVvac vaccine which contains polyepitope B and T- cell immunogens of HIV-1.

Authors:  L I Karpenko; S I Bazhan; A M Eroshkin; L R Lebedev; R V Uzhachenko; N A Nekrasova; O A Plyasunova; P A Belavin; S V Seregin; N K Danilyuk; E D Danilenko; B N Zaitsev; V I Masicheva; A A Ilyichev; L S Sandakhchiev
Journal:  Dokl Biochem Biophys       Date:  2007 Mar-Apr       Impact factor: 0.788

2.  Immune responses induced in HHD mice by multiepitope HIV vaccine based on cryptic epitope modification.

Authors:  Yinghui Li; Yuxiao Huang; Jiao Liang; Zhikai Xu; Yan Shen; Ning Zhang; Zhongxiang Liu; Ya Zhao
Journal:  Mol Biol Rep       Date:  2013-03-01       Impact factor: 2.316

3.  Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice.

Authors:  Takahiro Okazaki; Masaki Terabe; Andrew T Catanzaro; C David Pendleton; Robert Yarchoan; Jay A Berzofsky
Journal:  J Virol       Date:  2006-08-18       Impact factor: 5.103

4.  Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.

Authors:  James T Snyder; Igor M Belyakov; Amiran Dzutsev; François Lemonnier; Jay A Berzofsky
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

5.  HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responses.

Authors:  Rachid Boucherma; Hédia Kridane-Miledi; Romain Bouziat; Michael Rasmussen; Tanja Gatard; Francina Langa-Vives; Brigitte Lemercier; Annick Lim; Marion Bérard; Lbachir Benmohamed; Søren Buus; Ronald Rooke; François A Lemonnier
Journal:  J Immunol       Date:  2013-06-17       Impact factor: 5.422

6.  The HIV-1 antisense protein (ASP) induces CD8 T cell responses during chronic infection.

Authors:  Anne Bet; Emmanuel Atangana Maze; Anju Bansal; Sarah Sterrett; Antoine Gross; Stéphanie Graff-Dubois; Assia Samri; Amélie Guihot; Christine Katlama; Ioannis Theodorou; Jean-Michel Mesnard; Arnaud Moris; Paul A Goepfert; Sylvain Cardinaud
Journal:  Retrovirology       Date:  2015-02-10       Impact factor: 4.602

7.  Vpx-containing dendritic cell vaccine induces CTLs and reactivates latent HIV-1 in vitro.

Authors:  T D Norton; E A Miller; N Bhardwaj; N R Landau
Journal:  Gene Ther       Date:  2015-01-08       Impact factor: 5.250

8.  Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE.

Authors:  Yi-Hsiang Huang; Masaki Terabe; C David Pendleton; Deborah Stewart Khursigara; Tapan K Bera; Ira Pastan; Jay A Berzofsky
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.